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Background. The prognosis of patients with advanced oropharyngeal carcinoma (OPSCC) is generally poor. The aim of this study
is to investigate the different therapeutic approaches and identify prognostic factors associated with a worse outcome for patients
treated for T4a OPSCC, in order to improve treatment selection for the individual.Methods. A retrospective study was conducted
on 426 patients with T4a OPC treated between 1980 and 2010. Eleven prognostic factors including treatment modality, lymph
node staging, and p16 status as a surrogate marker for human papillomavirus (HPV) infection were analyzed. Results. Univariate
analysis showed a significant difference in DSS between N0 and N+ (57.1% versus 26.9%, 𝑃 < 0.001), primary surgical and primary
nonsurgical treatment (52.7% versus 31.4%, 𝑃 < 0.001), and perinodal invasion (51.7% versus 19.9%, 𝑃 = 0.011). P16-negative
patients tended towards a worse DSS than p16-positive patients (40.2% versus 64.6%, 𝑃 = 0.126) but responded better to primary
surgery than to nonsurgical treatment (71.4% versus 34.0%, 𝑃 = 0.113). Multivariate analysis identified the N category as an
independent prognostic factor for survival. Conclusion. The survival of p16-negative patients was worse than p16-positive patients,
although they seem to respond better to primary surgery. The strongest independent prognostic factor for T4a carcinomas proved
to be the presence of lymph node metastases.
1. Introduction
The management of patients with locally advanced oropha-
ryngeal squamous cell carcinoma (OPSCC) has evolved
greatly. A decade ago, several studies showed that radio-
therapy (RT) in combination with chemotherapy (CT) offers
oncologic and functional results similar to those of surgery
but with lower severe complication rates [1–3]. Furthermore,
in the light of increasing importance of human papillo-
mavirus (HPV) infection in OPSCC and better survival after
radiochemotherapy (RCT) in this group of patients, primary
RCT has emerged as treatment of choice for this subset of
patients in many institutions [4, 5].
However, recent studies showed that both RT and CT
can cause serious morbidity such as dysphagia, mandibular
osteoradionecrosis, and pharyngeal strictures and may be
associated with higher mortality rates [6, 7]. Furthermore the
concept of organ preservation does not always coincide with
function preservation. On the other hand, other studies have
shown that the evolution of primary surgery, with the use of
CO
2
laser, robotic surgery, andmicrovascular reconstruction,
has reduced surgery-related morbidity and mortality and
improved function with even better oncologic results in some
cases [8–12]. The most appropriate treatment regimen is
therefore still controversial.
Prognostic factors are important in helping physicians to
select the best treatment modality for the individual patient
and for better planning of prospective studies. T4a tumors
were first defined in the 2002 TNM staging and represented a
unique study group, because although the tumor has invaded
critical structures it can still be resected surgically. To the best
of our knowledge, this is the largest study to assess oncologic
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outcome and prognostic factors in T4a OPC and also the first
study to examine the role of p16 expression as a marker for
HPV infection solely in this patient group [13].
2. Methods
A retrospective study was conducted at an academic tertiary
referral center (Department of Otorhinolaryngology, Head
and Neck Surgery, University of Erlangen-Nuremberg Med-
ical School, Erlangen, Germany). Patients referred to our
hospital between 1980 and 2010, who had received definitive
treatment for previously untreated squamous cell carcinomas
of the oropharynx, were considered for selection. The study
included all patients who had a cT4a Nall M0 tumor if not
treated with primary operation and pT4a if primary surgical
treatment was applied (stage IVa or IVb). Exclusion criteria
were previous treatment for head and neck carcinomas,
distant metastases at the time of diagnosis, histology other
than SCC, and patients with second primary tumors at the
time of diagnosis. The institutional review board approved
the study.
After reviewing the pretherapeutic imaging and the
surgical and the pathology reports, staging was reevaluated
according to the 2010 American Joint Committee on Cancer
(AJCC) and Union Internationale Contre le Cancer (UICC)
classification [14]. Since T4 carcinomas had been subdivided
into T4a and T4b in 2002, the files of patients with T4 tumors
treated prior to this date were carefully reassessed to differ-
entiate between T4a and T4b. In 31 cases this differentiation
was not possible and these patients were not included for
further evaluation. Following clinical examination, standard
diagnostic investigations included ultrasonography and com-
puted tomography. Magnetic resonance imaging (MRI) was
also used in a few cases. The appropriate treatment modality
was decided by our interdisciplinary tumor board. Factors
influencing the decision were the operability of the tumor,
general health, and personal preference of each patient.
The endpoints for the analysis were disease-specific sur-
vival (DSS), local control (LC), and regional control (RC).
DSS was defined as the time from the date of diagnosis
to death from the cancer or complications of treatment.
Duration of LC or RC was calculated from the date of
initial diagnosis to the date of most recent clinical review
when local or regional recurrence was confirmed. Local
recurrence was defined as invasive carcinoma at the anatomic
site of the primary tumor and regional recurrence as invasive
carcinoma in the lymph nodes of the neck, developing after
completion of the initial treatment. Calculations of five-year
overall survival (OS), disease-specific survival (DSS), local
control (LC), and regional control (RC) were made with
Kaplan-Meier estimates and compared using the log-rank
test. A 𝑃 value of less than 0.05 was considered significant.
Multivariate analysis was performed with backward stepwise
Cox regression using significant variables from the univariate
analysis. All statistical analyses were performed using SPSS
Version 20 (SPSS Inc., Chicago IL, USA).
Any HPV infection in tumor tissue was determined
retrospectively, using p16 immunohistochemistry as a highly
sensitive and specific surrogate marker for HPV-associated
carcinogenesis [15]. P16 immunohistochemistry was per-
formed using a primary antibody from Santa Cruz Biotech-
nology (clone JC8, dilution: 1 : 100). Tumors were considered
positive for p16when strong nuclear and cytoplasmic staining
was present in >60% of cells. The p16 oncoprotein expression
was successfully determined using paraffin blocks available
from 93 patients treated between 2000 and 2010. Character-
istics of the two groups were controlled using the chi-square
test.
3. Results
Initially 581 Patients were selected. Forty-five cases were
excluded because of second primary tumors at the time of
diagnosis, 53 patients because of distant metastases, and 57
patients because of incomplete treatment. The final study
population consisted of 426 patients who met the inclusion
criteria. There were 374 men and 52 women, with 7.2 : 1 male
to female ratio. The median age at presentation was 54 years
ranging from 32 to 82 (SD 9.9). Median follow-up was 1.64
years (range: 0–26.3). For surgically treated patients, median
follow-up was 1.54 years (range: 0–17.2) and for nonsurgically
treated patients follow-up was 2.11 years (range: 0–26.3).
245 (57.5%) patients were smokers, 51 (11.9%) exsmokers,
and 21 (4.9%) nonsmokers. Information about smoking
was not available for 109 (25.6%) patients. 237 (55.6%)
patients drank alcohol, 48 (11.3%) were exdrinkers, and
28 (6.6%) teetotalers. No information was available for 115
patients.
The five-year OS was 21.6% (95% CI: 17–26%), DSS 35.6%
(95% CI: 30–41%); LC was seen in 81.3% (95% CI: 77–
86%) and RC in 89% (95% CI: 84–94%). There was a local
recurrence in 65 (15.6%) patients, a regional one in 22 (5.16%),
and distant metastasis in 27 (6.3%) of the 426 patients. Mean
time to the first local recurrence was 0.47 years.
Two major groups were defined according to the type
of management. The first group consisted of 316 patients
who received radiotherapy with or without concomitant
chemotherapy (RCT group) and salvage surgery in some
cases. The second group of 83 patients received primary
surgical treatment with or without adjuvant radio- (or
chemo)therapy. Table 1 shows survival estimates in relation
to treatment modality. The prognosis was found to differ
significantly between the two groups. Univariate analysis
showed that the surgery group had a significantly better DSS
(𝑃 < 0.001) and OS (𝑃 < 0.001) in comparison with the RCT
group. On the other hand, LC and RC were compara-
ble in the two groups. Figure 1 presents the Kaplan-Meier
curve of DSS in relation to the primary treatment group.
A specific comparison of only those cases with combined
treatment modalities showed that both DSS and OS were
statistically better following surgery with adjuvant radio-
or radiochemotherapy (64 patients) in comparison with
combined primary chemoradiotherapy with or without sal-
vage surgery (151 patients) (OS = 44.4% [95% CI: 32–
57%] versus 18.6% [95% CI: 12–25%], 𝑃 < 0.001) (DSS
= 53.5% [95% CI: 40–67%] versus 33.8% [95% CI: 24–42],
𝑃 < 0.001). Twenty-seven patients could not be included
in either of the two groups because they had only palliative
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Table 1: Oncologic results according to treatment group.
Treatment group Number of patients 5-Y-KM-Estimate (%) (total number of events) (95% CI)
OS DSS LC RC DC















Surgery + RT 38 38.9 (33) (21–52) 41.8 (20)(25–58)
∗75.7 (8) (6–91) ∗81.6 (5) (67–96)
∗90.0 (2)
(76–100)






(87–100) 56.7 (18) (37–76)









RCT ± salvage 151 18.6 (129)(12–25) 33.8 (91) (24–42) 83.5 (21) (76–91)
∗96.0 (4)
(92–100) 76.8 (11) (62–91)
RT ± salvage 165 16.8 (134)(11–23) 29.6 (93) (21–38) 84.2 (22) (78–91)
∗88.8 (7)
(80–98) 83.0 (9) (71–95)











Primary nonsurgical group censored
Primary surgical group censored
Primary nonsurgical group
Primary surgical group
Disease specific survival according to therapy group
Figure 1: DSS (disease-specific survival) estimates according to
treatment group (52.7% 95% CI 41–65% versus 31.4% 95% CI 23–
39%, 𝑃 = 0.001).
therapy (e.g., only chemotherapy or postchemotherapy sal-
vage surgery).
Evidence of regional disease was found in 303 cases.
Table 2 shows survival according to the clinical N category.
For the statistical analysis, patients were grouped in cN0 and
cN+ cases. As shown in Table 4, patients who were cN0 had
significantly better DSS and OS. Of the patients classified as
cN0 who underwent primary surgical therapy (13), 9 had
an elective neck dissection. Three out of nine patients had
evidence of regional metastases on histopathology, giving an
occult metastasis rate of 33.3%.
Immunohistochemical p16 oncoprotein expression was
determined in 93 patients. Fifteen proved to be p16-positive,
while 78 were p16-negative, giving a rate of 16%. The mean
age of the former groupwas 56.2 and that of the latter was 62.8
years. Univariate analysis revealed a better DSS (64.6% versus
40.2%, 𝑃 = 0.126) and OS (40.2% versus 23.4%, 𝑃 = 0.388)
for p16-positive cases but the differences were not statistically
significant. Table 3 shows the oncologic results in relation to
the therapy group for p16-positive and p16-negative patients
separately. Three cases could not be included in either of
the treatment groups, so that 90 patients were analyzed. The
small number of p16-positive patients did not allow for a
statistical comparison of the two treatment groups. On the
other hand, patients who were p16-negative showed a trend
towards better survival following primary surgery than after
primary conservative treatment. Figures for OS were 50.0%
versus 19.1% (𝑃 = 0.102) and forDSSwere 71.4% versus 34.0%
(𝑃 = 0.113), respectively.
Of the 83 patients who underwent primary surgical
treatment, clear surgical margins (R0) were achieved in 64
patients (77.1%), while resections had positive margins (R+)
in the remaining 19 patients (22.9%). As Table 4 shows,
patients with R0 resections had better DSS, OS, and distal
metastasis rates.Nineteen of the surgical patients did not have
a neck dissection, however, and they showed significantly
worse DSS and OS.
Table 4 shows the results of univariate analysis of eleven
potential prognostic factors. Statistical analysis of perinodal
and lymphatic invasion was flawed because of the small
number of cases in one group. Nevertheless, patients without
perinodal invasion had better DSS and OS. Female patients
showed a trend towards better DSS and OS. Lastly, age and
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Table 2: Oncologic results according to cN category.
N category Number of patients 5-Y-KM-Estimate (%) (Total number of events) (95% CI)
OS DSS LC RC DC
N0 115 40.3 (85) (31–50) 57.1 (43) (47–67) 83.5 (18) (76–91) ∗91.5 (6) (84–99) ∗85.7 (9) (77–95)
N1 35 17.1 (31) (5–30) 31.7 (22) (14–49) ∗80.0 (7) (67–93) ∗75.9 (3) (50–1) No events∗
N2 222 13.6 (191) (9–19) 27.7 (132) (20–35) 79.6 (31) (71–88) ∗91.9 (8) (86–97) 79.3 (15) (68–91)
N3 46 15.8 (40) (5–27) 20.5 (32) (8–33) ∗80.8 (7) (67–94) ∗80.7 (5) (63–99) ∗76.0 (3) (51–100)
N𝑥 8 ∗25.0 (7) (0–55) ∗33.3 (5) (0–71) ∗72.9 (2) (41–1) No events∗ No events∗
Table 3: Oncologic results according to HPV infection and treatment group.
p16 Treatment group(number of patients)
5-Y-KM-Estimate (%) (Total number of events) (95% CI)
OS DSS LC RC DC
∗p16-positive
Primary surgical group (5)
∗75.0 (2)













































∗Not enough events or patients for statistical analysis.
tumor differentiation did not affect survival. The base of the
tongue and the tonsillar region (i.e., tonsil, tonsillar fossa, and
pillars) were the most commonly affected subsites. As seen
in Table 4, univariate analysis did not reveal any significant
differences in survival according to the affected anatomic
subsite.
A multivariate analysis of appropriate variables was then
performed. The N category proved to be a statistically
significant independent predictor of reduced DSS (OR =
2.662; P (Wald) = 0.001; 95% CI 1.709 to 4.145) and OS (OR =
2.255; P (Wald) = 0.003; 95% CI 1.327 to 3.834).
4. Discussion
The incidence of OPSCC has been increasing continuously in
recent years, a development that has been attributedmainly to
HPV infection [16, 17]. Although advances in high-precision
radiotherapy and new systemic agents havemade nonsurgical
treatment of advanced OPSCC, the standard care in many
centers, the most appropriate treatment regimen is still the
subject of debate [18–20].The prognostic value of HPV infec-
tion has gained importance in clinical research, especially of
OPSCC [16, 21]. The expression of p16, which is a surrogate
marker for HPV, is usually measured [17]. Nevertheless, a
large proportion of patients have HPVnegative OPSCC and,
for this reason, their optimal treatment modality should not
be neglected [22].
In our study, OPSCC with probably HPV-related patho-
genesis represented 16% of cases; this is lower than in recent
studies [21] which showed proportions of 40.5–72.2% [23,
24]. There are two explanations for this phenomenon: first,
the relatively low proportion of HPV-related oropharyngeal
carcinoma in Germany compared to other regions [25] and
second, the advanced T category. Patients with HPV-related
carcinoma are younger and more discerning and therefore
seekmedical help before the tumor becomes locally advanced
(T4a) [17]. In consequence, the majority of patients with T4a
carcinoma treated in Germany are HPV-negative OPSCC.
Our study is consistent with previouswork that demonstrated
worse survival rates for HPV-negative patients [5, 21, 25].
Although our results were not statistically significant, this can
be attributed to the small number of p16-positive patients. In
fact the lowpercentage of patientswith information about p16
status (93/426) is a weakness of this study.
The poor survival of HPV-negative patients with locally
advancedOPSCCmakes it essential that treatmentmodalities
be improved for this large patient group, as the optimal
treatment regimen has yet to be found. This is in contrast to
patients with HPV-positive tumor or with early OPSCC, for
whom deescalation of treatment is being discussed [26, 27].
A prospective study comparing primary surgical treatment
and primary conservative treatment is unlikely to be realized,
since patient and clinician preferences would make recruit-
ment almost impossible. As long as prospective randomized
data are lacking, however, nonrandomized data, such as
those presented in our study, may offer a basis for treatment
decision making.
Our data show a trend toward better OS and DSS for the
primary surgically treated patients with HPV-negative T4a
OPSCC. Of course, it could be argued that there is a selection
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bias in the two treatment modalities. In fact the major weak-
ness of the study is the selection bias in a historical cohort
covering a 30-year era of various types and protocols in the
treatment decision making. Therefore, this study should not
be considered as a direct comparison between surgery and
RCT.The study does, however, present evidence that primary
surgery might have a clear role in advanced HPV-negative
OPSCC. Other studies have also shown a survival benefit
in surgical patients [19, 28]. In the case of primary surgery,
our study confirmed the prognostic impact of clear resection
margins (R0), emphasizing their importance in survival [29].
The high percentage of incomplete tumor resection in our
study (22.9%) can partially be explained by inadequate patho-
logic assessment of frozen sections and surgical approach and
emphasizes the need for the careful preoperative selection of
patients and the painstaking surgical technique required to
optimize oncologic results. Furthermore the high percentage
of nonsurgically treated patients in this study (316/426) shows
that primary radiochemotherapy remains the treatment of
choice in most cases with advanced OPSCC.
Another promising therapeutic alternative currently
being investigated for advanced OPSCC is the use of induc-
tion chemotherapy followed by concomitant chemoradiation
or surgery [30–32]. In a recent phase III trial, the additional
use of panitumumab in patients receiving primary radiother-
apy and cisplatin significantly improved survival in HPV-
negative patients [33].
Prognostic factors are important in selecting the appro-
priate treatment for the patient. Furthermore, prognostic fac-
tors can help proper stratification in future randomized trials.
Our study investigated eleven possible prognostic factors for
the oncologic outcome in T4a oropharyngeal carcinoma.The
strongest prognostic factor for T4a carcinomas in univariate
and multivariate analysis proved to be the presence of lymph
node metastases. Perhaps future trials could investigate the
oncologic safety of deescalation of treatment inHPV-positive
patients with cN0 neck. The incidence of occult metastases
was 33%, which is comparable to previous studies and
confirms the need for elective treatment of the neck [34–36].
Perinodal invasion was also shown to be a significant prog-
nostic factor but the widely different group sizes reduced the
power of the statistical analysis. Interestingly, recent studies
could not verify the prognostic importance of extracapsular
spread in HPV-positive OPSCC, and the authors concerned
suggest deescalating adjuvant therapy in this patient group,
even if there is evidence of ECS [27].
In the present study, 155 of the initial 581 patients were
excluded because they did not meet the inclusion criteria.
Fifty-seven (19.8%) of them were excluded because they
were not able to receive proper treatment. This percentage is
comparable with the literature and shows that many patients
with advanced OPSCC are not able to receive the intended
curative treatment, a problem that is often ignored in many
studies [37].
5. Conclusion
HPV-positive cases seem to account for a low proportion of
T4a OPSCC in our patient cohort (16%) and further studies
should investigate if this percentage increases with time.
HPV-negative patients, on the other hand, hadworse survival
but performed better after primary surgical treatment. The
strongest independent prognostic factor for T4a carcinomas
in multivariate analysis proved to be the presence of cervical
lymph node metastases (pN+).
6. Synopsis
The strongest independent prognostic factor for T4a carcino-
mas proved to be the presence of lymph nodemetastases.The
survival of p16-negative patients was worse than p16-positive
patients, although they seem to respond better to primary
surgery.
Acronyms
OPSCC: Oropharyngeal squamous cell carcinoma
RT: Radiotherapy
RCT: Radiochemotherapy
SCC: Squamous cell carcinoma
AJCC: American Joint Committee on Cancer
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